Aadi Bioscience (AADI) Competitors

$4.49 +0.19 (+4.42%)

As of 05/22/2026

AADI vs. ACB, CRBU, KPTI, SLGL, and CRBP

Should you buy Aadi Bioscience stock or one of its competitors? MarketBeat compares Aadi Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aadi Bioscience include Aurora Cannabis (ACB), Caribou Biosciences (CRBU), Karyopharm Therapeutics (KPTI), Sol-Gel Technologies (SLGL), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical products" industry.

How does Aadi Bioscience compare to Aurora Cannabis?

Aadi Bioscience (NASDAQ:AADI) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Aurora Cannabis has a net margin of -23.46% compared to Aadi Bioscience's net margin of -246.06%. Aurora Cannabis' return on equity of -0.04% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Aurora Cannabis	-23.46%	-0.04%	-0.03%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aurora Cannabis has higher revenue and earnings than Aadi Bioscience. Aurora Cannabis is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.42	-$65.76M	-$2.35	N/A
Aurora Cannabis	$246.72M	0.83	$1.63M	-$1.08	N/A

In the previous week, Aadi Bioscience and Aadi Bioscience both had 1 articles in the media. Aurora Cannabis' average media sentiment score of 0.66 beat Aadi Bioscience's score of 0.35 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aadi Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurora Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Summary

Aurora Cannabis beats Aadi Bioscience on 9 of the 14 factors compared between the two stocks.

How does Aadi Bioscience compare to Caribou Biosciences?

Aadi Bioscience (NASDAQ:AADI) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Aadi Bioscience has a net margin of -246.06% compared to Caribou Biosciences' net margin of -1,189.14%. Aadi Bioscience's return on equity of -71.87% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market.

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aadi Bioscience and Aadi Bioscience both had 1 articles in the media. Aadi Bioscience's average media sentiment score of 0.35 beat Caribou Biosciences' score of 0.00 indicating that Aadi Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aadi Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aadi Bioscience has higher revenue and earnings than Caribou Biosciences. Aadi Bioscience is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.42	-$65.76M	-$2.35	N/A
Caribou Biosciences	$11.16M	18.66	-$148.12M	-$1.42	N/A

Caribou Biosciences has a consensus target price of $8.67, suggesting a potential upside of 312.70%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Caribou Biosciences beats Aadi Bioscience on 9 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Karyopharm Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

Karyopharm Therapeutics has a net margin of -129.02% compared to Aadi Bioscience's net margin of -246.06%. Karyopharm Therapeutics' return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Aadi Bioscience has higher earnings, but lower revenue than Karyopharm Therapeutics. Aadi Bioscience is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.42	-$65.76M	-$2.35	N/A
Karyopharm Therapeutics	$146.07M	1.27	-$196.04M	-$15.09	N/A

Karyopharm Therapeutics has a consensus target price of $17.17, suggesting a potential upside of 110.38%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Aadi Bioscience and Aadi Bioscience both had 1 articles in the media. Aadi Bioscience's average media sentiment score of 0.35 beat Karyopharm Therapeutics' score of 0.00 indicating that Aadi Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aadi Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Karyopharm Therapeutics beats Aadi Bioscience on 10 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Sol-Gel Technologies?

Aadi Bioscience (NASDAQ:AADI) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

In the previous week, Sol-Gel Technologies had 11 more articles in the media than Aadi Bioscience. MarketBeat recorded 12 mentions for Sol-Gel Technologies and 1 mentions for Aadi Bioscience. Sol-Gel Technologies' average media sentiment score of 1.01 beat Aadi Bioscience's score of 0.35 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Sol-Gel Technologies	Positive

Sol-Gel Technologies has lower revenue, but higher earnings than Aadi Bioscience. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.42	-$65.76M	-$2.35	N/A
Sol-Gel Technologies	$19.39M	11.12	-$6.13M	-$2.23	N/A

Sol-Gel Technologies has a consensus target price of $110.00, suggesting a potential upside of 43.36%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sol-Gel Technologies	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Sol-Gel Technologies has a net margin of -31.60% compared to Aadi Bioscience's net margin of -246.06%. Sol-Gel Technologies' return on equity of -24.29% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Sol-Gel Technologies	-31.60%	-24.29%	-18.73%

Summary

Sol-Gel Technologies beats Aadi Bioscience on 14 of the 17 factors compared between the two stocks.

How does Aadi Bioscience compare to Corbus Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Corbus Pharmaceuticals has a beta of 2.68, suggesting that its share price is 168% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Corbus Pharmaceuticals has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Corbus Pharmaceuticals' return on equity of -70.89% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for Corbus Pharmaceuticals and 1 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.35 beat Corbus Pharmaceuticals' score of 0.27 indicating that Aadi Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Aadi Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aadi Bioscience has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Aadi Bioscience	$25.07M	4.42	-$65.76M	-$2.35	N/A

Corbus Pharmaceuticals currently has a consensus price target of $42.89, suggesting a potential upside of 277.88%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Corbus Pharmaceuticals is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Corbus Pharmaceuticals beats Aadi Bioscience on 10 of the 16 factors compared between the two stocks.

Get Aadi Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AADI vs. The Competition

Export

Metric	Aadi Bioscience	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$110.89M	$927.43M	$6.45B	$12.34B
Dividend Yield	N/A	4.84%	2.76%	5.28%
P/E Ratio	-1.97	1.46	21.22	25.65
Price / Sales	4.42	119.63	553.92	86.28
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	1.05	7.59	10.37	7.14
Net Income	-$65.76M	-$3.64M	$3.57B	$335.98M
7 Day Performance	-4.47%	1.93%	6.01%	3.56%
1 Month Performance	11.41%	76.78%	3.52%	2.54%
1 Year Performance	155.11%	126.62%	34.13%	35.05%

Aadi Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AADI Aadi Bioscience	N/A	$4.49 +4.4%	N/A	+155.1%	$110.89M	$25.07M	N/A	40	Gap Up
ACB Aurora Cannabis	0.9465 of 5 stars	$3.36 -1.8%	N/A	-37.1%	$202.14M	$246.72M	N/A	1,130	Gap Up
CRBU Caribou Biosciences	1.7392 of 5 stars	$2.03 flat	$8.67 +326.9%	+105.9%	$201.34M	$11.16M	N/A	100	Gap Down
KPTI Karyopharm Therapeutics	2.3005 of 5 stars	$8.91 +1.1%	$17.17 +92.7%	+77.8%	$198.68M	$146.07M	N/A	380
SLGL Sol-Gel Technologies	3.6121 of 5 stars	$67.21 -4.0%	$110.00 +63.7%	+910.9%	$196.63M	$19.39M	N/A	50	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AADI) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aadi Bioscience (AADI) Competitors

AADI vs. ACB, CRBU, KPTI, SLGL, and CRBP

How does Aadi Bioscience compare to Aurora Cannabis?

Summary

How does Aadi Bioscience compare to Caribou Biosciences?

Summary

How does Aadi Bioscience compare to Karyopharm Therapeutics?

Summary

How does Aadi Bioscience compare to Sol-Gel Technologies?

Summary

How does Aadi Bioscience compare to Corbus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aadi Bioscience (AADI) Competitors

AADI vs. ACB, CRBU, KPTI, SLGL, and CRBP

How does Aadi Bioscience compare to Aurora Cannabis?

Is AADI or ACB more profitable?

Do analysts prefer AADI or ACB?

Which has stronger earnings and valuation, AADI or ACB?

Does the media prefer AADI or ACB?

Do insiders & institutionals have more ownership in AADI or ACB?

Which has more volatility & risk, AADI or ACB?

Summary

How does Aadi Bioscience compare to Caribou Biosciences?

Is AADI or CRBU more profitable?

Which has more volatility and risk, AADI or CRBU?

Do institutionals and insiders have more ownership in AADI or CRBU?

Does the media prefer AADI or CRBU?

Which has better valuation and earnings, AADI or CRBU?

Do analysts rate AADI or CRBU?

Summary

How does Aadi Bioscience compare to Karyopharm Therapeutics?

Which has more volatility & risk, AADI or KPTI?

Is AADI or KPTI more profitable?

Which has better earnings and valuation, AADI or KPTI?

Do analysts rate AADI or KPTI?

Do insiders & institutionals hold more shares of AADI or KPTI?

Does the media refer more to AADI or KPTI?

Summary

How does Aadi Bioscience compare to Sol-Gel Technologies?

Does the media prefer AADI or SLGL?

Which has better earnings & valuation, AADI or SLGL?

Do analysts rate AADI or SLGL?

Do insiders and institutionals have more ownership in AADI or SLGL?

Which has more risk and volatility, AADI or SLGL?

Is AADI or SLGL more profitable?

Summary

How does Aadi Bioscience compare to Corbus Pharmaceuticals?

Which has more volatility & risk, CRBP or AADI?

Is CRBP or AADI more profitable?

Do institutionals & insiders have more ownership in CRBP or AADI?

Does the media favor CRBP or AADI?

Which has preferable earnings & valuation, CRBP or AADI?

Do analysts prefer CRBP or AADI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools